Thymic carcinoma: State of the art review

Tony Y. Eng, Clifton D. Fuller, Jaishree Jagirdar, Yadvindera Bains, Charles R. Thomas

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Abstract

Thymic carcinoma is a rare neoplasm with distinct clinical and pathological characteristics. The prognosis is often poor with an aggressive course that belies its numerical rarity. Potentially prognostic factors for survival include histopathologic grade, clinical stage, and resectability of the tumor. Five-year survival rates for all patients are approximately 30-50%, with a significant survival time differential between low-grade and high-grade neoplasms. Owing to the paucity of cases, optimal management of thymic carcinoma has yet to be defined. At present, a multimodality approach involving aggressive surgical resection, platinum-based combination chemotherapeutic interventions, and radiotherapy represent the preferred therapeutic approach. Though our knowledge remains somewhat speculative at present, several scientific, technological and therapeutic innovations may have a potentially significant impact on the future of this disease.

Original languageEnglish (US)
Pages (from-to)654-664
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume59
Issue number3
DOIs
StatePublished - Jul 1 2004

Keywords

  • Chemotherapy
  • Radiation therapy
  • Review Mediastinum
  • Surgery
  • Thymic carcinoma

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Thymic carcinoma: State of the art review'. Together they form a unique fingerprint.

Cite this